第一线抗抑郁药使用与老年人痴呆风险之间的关联:一项回顾性队列研究
Grace Hsin-Min Wang1, Wei-Han Chen1, Shao-Hsuan Chang1
1Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, 1225 Center Drive, HPNP 3338, Gainesville, FL, 32610, USA.
BMC geriatrics
|December 9, 2023
概括
与接受心理治疗的人相比,使用抗抑郁药 (SSRI/SNRIs) 的抑郁症老年人患痴呆的风险更高. 这项研究强调了与抗抑郁药在痴呆症预防中的使用相关的潜在风险.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 以前的研究表明,抗抑郁药的使用与痴呆症风险增加之间存在潜在联系,可能是由于混因素.
- 这项研究解决了对老年人抑郁症药物治疗和心理治疗之间的风险区分的需要.
研究的目的:
- 为了比较使用一线抗抑郁药 (SSRI/SNRIs) 与心理治疗治疗的抑郁症老年人的痴呆风险.
主要方法:
- 一项回顾性队列研究利用了美国医疗支出小组调查数据 (2010-2019).
- 包括50岁以上的成年人,抑郁症开始SSRI/SNRI或心理治疗,不包括那些先前被诊断患有痴呆症的人.
- 使用逻辑回归,在2年内评估痴呆风险,并进行子组分析.
主要成果:
- 在2,710名参与者中,89%使用SSRI/SNRIs,11%接受心理治疗.
- 与心理治疗使用者 (11.8%) 相比,SSRI/SNRI使用者的痴呆发病率 (16.4%) 较高.
- 调整后的概率比为1.36 (95% CI:1.06-1.74) 表明SSRI/SNRI使用增加了痴呆风险.
结论:
- 与接受心理治疗的人相比,患有抑郁症的老年人开始使用SSRI/SNRIs时面临着更高的痴呆风险.
- 研究结果表明,需要仔细考虑老年人抑郁症的治疗选择,以减轻痴呆症风险.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
247
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
247
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
400
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
400
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Antidepressant Drugs: Overview
509
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
509
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492


